Overview

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dose administration of chemotherapy on angiogenesis, and correlate this with tumor responses.
Phase:
Phase 2
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Treatments:
Angiogenesis Inhibitors
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Levofloxacin
Ofloxacin
Rituximab
Vincristine